Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538850 | 1.00 | TBXAS1 (1.00) | TBXAS1EGLN3 | |
| SCHEMBL5539944 | 1.00 | TBXAS1 (1.00) | TBXAS1EGLN3 | |
| SCHEMBL3137867 | 1.00 | TBXAS1 (1.00) | TBXAS1EGLN3 | |
| SCHEMBL5535247 | 1.00 | TBXAS1 (1.00) | TBXAS1EGLN3 | |
| SCHEMBL5533203 | 1.00 | TBXAS1 (1.00) | TBXAS1EGLN3 | |
| SCHEMBL11272759 | 1.00 | TBXAS1 (1.00) | TBXAS1EGLN3 | |
| SCHEMBL11269252 | 1.00 | TBXAS1 (1.00) | TBXAS1EGLN3 | |
| SCHEMBL5531525 | 1.00 | TBXAS1 (1.00) | TBXAS1EGLN3 | |
| SCHEMBL5541351 | 1.00 | TBXAS1 (1.00) | TBXAS1EGLN3 | |
| SCHEMBL5536323 | 1.00 | TBXAS1 (1.00) | TBXAS1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116718657-A | Preparation method of glucose biological sensing membrane and glucose biological sensor | 深圳木芯科技有限公司 | 2023-09-08 | — | — | CN | claimed |
| EP-0351755-B1 | COMBINATION OF A CALCIUM CHANNEL BLOCKER AND THROMBOXANE A2 RECEPTOR ANTAGONIST OR SYNTHETASE INHIBITOR AND METHOD FOR TREATING ISCHEMIA EMPLOYING SUCH COMBINATION | E.R. SQUIBB & SONS, INC. (US) | 1992-09-30 | — | — | EP | claimed |
| EP-0351755-A1 | Combination of a calcium channel blocker and thromboxane A2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination | E.R. SQUIBB & SONS, INC. (US) | 1990-01-24 | — | — | EP | claimed |
| CN-116718657-A | Preparation method of glucose biological sensing membrane and glucose biological sensor | 深圳木芯科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-114787200-A | Method for forming inclusion complex using hydrophilic beta-cyclodextrin derivatives and compositions thereof | 塔卡美国公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20200347153-A1 | METHODS FOR FORMING INCLUSION COMPLEXES WITH HYDROPHILIC BETA-CYCLODEXTRIN DERIVATIVES AND COMPOSITIONS THEREOF | TAKA USA, INC. (US) | 2020-11-05 | — | — | US | disclosed |
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | LUBIT BEVERLY W | 2011-01-06 | — | — | US | disclosed |
| CN-100543032-C | Streptogramin derivatives, preparation method and compositions containing them | AVETIS PHARMA S A (FR) | 2009-09-23 | — | — | CN | disclosed |
| CN-1961878-A | Streptogramin derivatives, their preparation and compositions containing them | AVENTIS PHARMA SA (FR) | 2007-05-16 | — | — | CN | disclosed |
| US-20070044831-A1 | Electrolyte composition and dye-sensitized solar cell | NATIONAL UNIVERSITY CORPORATION KYUSHU INSTITUTE OF TECHNOLOGY (JP) | 2007-03-01 | — | — | US | disclosed |
| CN-1358194-A | Streptogramin derivatives, preparation method and compositions containing them | AVETIS PHARMA S A (FR) | 2002-07-10 | — | — | CN | disclosed |
| EP-0297621-B1 | Cyclic amino-thioacetal amides, a process for the preparation thereof and pharmaceutical compositions containing them | BOEHRINGER MANNHEIM ITALIA (IT) | 1994-09-21 | — | — | EP | disclosed |
| US-H1139-H | Reduced myocardial infarction size and angina pain; prevention of reocclusion with no adverse side effects | E. R. SQUIBB & SONS, INC. (US) | 1993-02-02 | — | — | US | disclosed |
| EP-0351755-B1 | COMBINATION OF A CALCIUM CHANNEL BLOCKER AND THROMBOXANE A2 RECEPTOR ANTAGONIST OR SYNTHETASE INHIBITOR AND METHOD FOR TREATING ISCHEMIA EMPLOYING SUCH COMBINATION | E.R. SQUIBB & SONS, INC. (US) | 1992-09-30 | — | — | EP | disclosed |
| US-4988701-A | Cyclic amino-thioacetal amides, a process for the preparation thereof and pharmaceutical compositions | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1991-01-29 | — | — | US | disclosed |
| EP-0351755-A1 | Combination of a calcium channel blocker and thromboxane A2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination | E.R. SQUIBB & SONS, INC. (US) | 1990-01-24 | — | — | EP | disclosed |
| EP-0297621-A2 | Cyclic amino-thioacetal amides, a process for the preparation thereof and pharmaceutical compositions containing them | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1989-01-04 | — | — | EP | disclosed |
| US-4355170-A | ANTIINFLAMMATORY, HYPERTENSIVE, ANTIASTHMATIC AGENTS, A THROMBOXANE SYNTHETASE INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-10-19 | — | — | US | disclosed |
| US-4320134-A | HYPOTENSIVE, ANTIASTHMATIC AND ANTIINFLAMMATORY AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-03-16 | — | — | US | disclosed |
| US-4256757-A | ANTIINFLAMMATORY AND HYPOTENSIVE AGENTS; THROMBOSIS; ASTHMA; NERVOUS SYSTEM DISORDERS | ONO PHARMACEUTICAL CO., LTD. | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110002866-A1 | METHODS TO PREVENT A HAIR-RELATED SIDE EFFECT OF TREATMENT WITH A CHEMOTHERAPEUTIC AGENT | PGF, PTGS1, PTGS2 | TBXAS1 3617/4885EGLN3 202/4885 |
| US-20200347153-A1 | METHODS FOR FORMING INCLUSION COMPLEXES WITH HYDROPHILIC BETA-CYCLODEXTRIN DERIVATIVES AND COMPOSITIONS THEREOF | DSC1, PDCD2L, GANC | TBXAS1 4363/4885EGLN3 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.